Product logins

Find logins to all Clarivate products below.


In 2023, sales of branded MAb biologics in oncology exceeded $47 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5.5 billion. Throughout the 2023-2033 forecast period, increasing numbers of branded biologics will lose patent protection, and biosimilars will enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and country / region.

Table of contents


Related Market Assessment Reports

Report
Breast Cancer | China In-Depth | China | 2024
The breast cancer therapy market is one of the most dynamic markets in the oncology space in mainland China. Several new and emerging therapies are set to be approved for select subpopulations;…
Report
Diabetic Macular Edema / Diabetic Retinopathy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Diabetic macular edema (DME), a complication of diabetic retinopathy (DR), develops as a result of persistently elevated blood sugar levels and can lead to vision loss or blindness if left…
Report
Systemic Lupus Erythematosus – Landscape & Forecast – Disease Landscape & Forecast (G7)
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment can be highly…
Report
Type 2 Diabetes – Landscape & Forecast – Disease Landscape & Forecast (G7)
The type 2 diabetes (T2D) therapy market will expand through 2034, supported by polypharmacy and the growing use of effective branded therapies offering nonglycemic benefits. Although the loss of…
Report
Osteoarthritic Pain – Landscape & Forecast – Disease Landscape & Forecast (G7)
Osteoarthritic (OA) pain is prevalent, debilitating, and challenging to manage. Current treatments, including intra-articular agents, NSAIDs, antidepressants, opioids, and antiepileptic drugs, are…